Vivani Medical, Inc. is a cutting-edge pharmaceutical company that is dedicated to improving the lives of patients with chronic diseases. Our focus is on developing long-term pharmaceutical implants that provide a steady release of medication over a period of six months or longer. This innovative approach aims to address the issue of medication non-adherence, a significant problem in healthcare today.
At the heart of our company is our proprietary NanoPortal™ platform, which allows for the development of tiny, sub-dermal drug implants. These implants offer a more convenient and effective alternative to traditional medication delivery methods, such as daily pills or injections. Our goal is to revolutionize the treatment of chronic diseases and provide patients with a better quality of life.
Currently, Vivani is focused on developing two miniature, long-term GLP-1 implants for the treatment of obesity and chronic weight management: NPM-115 (exenatide) and NPM-139 (semaglutide). These implants have the potential to significantly improve the lives of those struggling with obesity and its associated health complications.